Erik Gil-Ramon
Newcastle Upon Tyne, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: September 04, 2025
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma.
Journal: Nature communications
Published: May 04, 2025
Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening.
Journal: Hepatology communications
Published: October 03, 2024
Synthesis and preclinical evaluation of a 89Zr-labelled human single chain antibody for non-invasive detection of hepatic myofibroblasts in acute liver injury.
Journal: Scientific reports
Published: May 16, 2023
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.
Journal: Communications biology
Published: April 11, 2023
Harnessing neutrophil plasticity for HCC immunotherapy.
Journal: Essays in biochemistry
Published: February 16, 2023
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.
Journal: Hepatology (Baltimore, Md.)
Published: May 23, 2022
Key features of the environment promoting liver cancer in the absence of cirrhosis.
Journal: Scientific reports
Published: May 09, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: November 25, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026